Beyond The "Blueprint": The Next Stage For US HHS Drug Price Policy

Upcoming transition in HHS drug pricing policy staff reinforces the Trump Administration's shift away from the 2018 "Blueprint” and towards engaging with bipartisan Congressional legislation – and spotlighting executive action as coming from the White House in the context of the upcoming Presidential campaign.

Blueprint-light-bulb

US Center for Medicare principal deputy director John Brooks will add responsibility for the Department of Health & Human Services drug pricing policy to his portfolio following the departure of senior advisor on Drug Pricing John O’Brien, who will be leaving his position later this month. HHS Secretary Alex Azar announced the changes on 12 August.

In one sense, the transition sends a message of continuity: Brooks’ first role at HHS was as a senior counselor to the HHS Secretary (then Tom Price)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

More from Market Access